STOCK TITAN

PROVECTUS BIOPHARMACEUTICALS (PVCT) SEC Filings, Dec 2025-Feb 2026

PVCT OTC
Rhea-AI Summary

Provectus Biopharmaceuticals CEO Edward Pershing reported acquiring an 8% unsecured convertible promissory note from the company on February 12, 2026. The note has a principal amount of $30,000 and may be converted into Series D-1 Convertible Preferred Stock at $2.862 per share.

The outstanding principal and interest on the note will automatically convert into Series D-1 preferred stock twelve months after the note’s issue date. Each Series D-1 preferred share is convertible into 10 shares of common stock and will automatically convert into common stock on December 31, 2028 unless converted earlier under its terms.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.21%
Tags
insider
-
Rhea-AI Summary

Pershing Edward reported open-market purchase transactions in a Form 4 filing for PVCT. The filing lists transactions totaling 34,940 shares at a weighted average price of $2.86 per share. Following the reported transactions, holdings were 2,613,807 shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.65%
Tags
insider
-
Rhea-AI Summary

Provectus Biopharmaceuticals CEO Edward Pershing, who also serves as a director, reported receiving an 8% unsecured convertible promissory note on February 5, 2026. The note can be converted into shares of Series D-1 Convertible Preferred Stock at a price of $2.862 per share.

Under the terms described, each share of Series D-1 preferred is convertible into 10 shares of common stock. The Series D-1 preferred will automatically convert into common stock on December 31, 2028, unless it is converted earlier under its certificate of designation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.32%
Tags
insider
Rhea-AI Summary

Provectus Biopharmaceuticals, Inc. amended the terms of its Series D and Series D-1 Convertible Preferred Stock to push back when these preferred shares automatically convert into common stock. The automatic conversion date, previously set at June 20, 2026, is now December 31, 2028.

The amendments were approved by the board of directors and a special committee made up entirely of independent directors, and were filed with the Delaware Secretary of State. The changes affect only the timing of automatic conversion, not the existence of the preferred stock itself.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.53%
Tags
current report
-
Rhea-AI Summary

Provectus Biopharmaceuticals CEO Edward Pershing converted debt into equity-linked securities. On January 30, 2026, an 8% unsecured convertible promissory note called the 2025 Note converted into 37,744 shares of Series D-1 Convertible Preferred Stock at a price of $2.862 per share.

Each share of Series D-1 Preferred Stock is convertible into 10 shares of common stock, and the preferred stock will automatically convert into common stock on June 20, 2026 unless converted earlier under its terms. After this transaction, Pershing directly beneficially owned 2,578,867 shares of Series D-1 Convertible Preferred Stock.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.53%
Tags
insider
-
Rhea-AI Summary

Provectus Biopharmaceuticals CEO and director Edward Pershing reported acquiring an 8% unsecured convertible promissory note on January 28, 2026. The note can be converted at any time into shares of Series D-1 Convertible Preferred Stock at a price of $2.862 per share.

The note’s outstanding principal and interest will automatically convert into Series D-1 Convertible Preferred Stock twelve months after its issue date, pursuant to the company’s 2025 Financing. Each share of Series D-1 Preferred Stock is convertible into 10 shares of common stock and will automatically convert into common stock on June 26, 2026, unless converted earlier under its terms.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.20%
Tags
insider
Rhea-AI Summary

Provectus Biopharmaceuticals CEO Edward Pershing reported a debt-for-equity conversion tied to prior financing. On January 16, 2026, an 8% unsecured convertible promissory note with $100,000 of outstanding principal and interest converted into 37,744 shares of Series D-1 Convertible Preferred Stock at $2.862 per share under the issuer's 2025 Financing. Each share of this preferred stock is convertible into 10 shares of common stock, and the Series D-1 Convertible Preferred Stock will automatically convert into common stock on June 20, 2026, unless converted earlier under its terms. Following this transaction, Pershing directly beneficially owned 2,541,123 derivative securities as reported in the Form 4.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.97%
Tags
insider
-
Rhea-AI Summary

Provectus Biopharmaceuticals, Inc. CEO and director Edward Pershing reported an insider transaction dated 12/11/2025 involving an 8% unsecured convertible promissory note. This note is treated as a derivative security linked to the company’s Series D-1 Convertible Preferred Stock.

Pershing may elect at any time to convert the note’s outstanding principal and interest into shares of Series D-1 Convertible Preferred Stock at a price of $2.862 per share. If he does not act earlier, the note will automatically convert into Series D-1 Preferred Stock twelve months after its issue date. Each share of Series D-1 Preferred Stock is convertible into 10 shares of common stock and will automatically convert into common stock on June 26, 2026, unless converted sooner according to its terms.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.33%
Tags
insider
-
Rhea-AI Summary

Provectus Biopharmaceuticals, Inc. reported an insider financing transaction involving its CEO and director, Edward Pershing. On 12/05/2025, he acquired an 8% unsecured convertible promissory note with an amount of $ 75,000. The note can be converted at any time into shares of Series D-1 Convertible Preferred Stock at a price of $ 2.862 per share, and will automatically convert into that preferred stock twelve months after its issue date as part of the company’s 2025 Financing.

Each share of Series D-1 Convertible Preferred Stock is convertible into 10 shares of Provectus common stock. The Series D-1 preferred shares will automatically convert into common stock on June 26, 2026, unless converted earlier under the terms of the Series D-1 Certificate of Designation. This transaction increases the CEO’s potential future equity exposure through layered conversions from debt to preferred stock and then to common shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.50%
Tags
insider
Rhea-AI Summary

Provectus Biopharmaceuticals, Inc. executive Dominic Rodrigues has filed a Schedule 13D reporting beneficial ownership of 25,220,549 shares of common stock, equal to 5.67% of the company’s outstanding common stock. This ownership includes shares held directly, through a retirement plan, jointly with his spouse, as custodian for children, and a large number of shares issuable from existing derivative securities.

The filing notes 13,378,760 shares of common stock are issuable upon conversion of 1,337,876 shares of Series D-1 Convertible Preferred Stock and 10,764,400 shares are issuable upon exercise of currently exercisable stock options. On December 2, 2025, 5,382,200 of his previously granted stock options vested. Rodrigues acquired these securities for investment purposes and, as Vice-Chairman and President, may influence the issuer’s corporate activities but states he has no specific current plans for major corporate transactions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.50%
Tags
other

FAQ

How many PROVECTUS BIOPHARMACEUTICALS (PVCT) SEC filings are available on StockTitan?

StockTitan tracks 65 SEC filings for PROVECTUS BIOPHARMACEUTICALS (PVCT), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for PROVECTUS BIOPHARMACEUTICALS (PVCT)?

The most recent SEC filing for PROVECTUS BIOPHARMACEUTICALS (PVCT) was filed on November 16, 2026.